RxDoctor Payments Data

Sarah Ruffin, NP

Primary Care · Colonial Heights, VANPI 1679031801

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Abbott at 38.8% of the total. Reporting peaked in 2021 at $755 and has fallen 97.6% since, to $18 in 2025.

$822in general payments, 2019–2025

Across 26 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$319
  • Boehringer Ingelheim$107
  • Boston Scientific$106
  • Johnson & Johnson$87
  • AstraZeneca$68
  • Novartis$40
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$822 in reported general payments places this provider in the 60th percentile of 142 primary care providers in Virginia.

See all primary care providers in Virginia

Medicare billing

Part B allowed, 2024
$31,745
Medicare patients
161
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$142,334
EntrestoSacubitril/Valsartan45$58,856
XareltoRivaroxaban32$43,110
JardianceEmpagliflozin31$35,884
Repatha SureclickEvolocumab17$12,623
Ezetimibe88$2,221
Metoprolol Succinate165$1,862
Atorvastatin Calcium139$1,420
Amlodipine Besylate115$879
Valsartan38$731
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$720
Torsemide18$676
Losartan Potassium61$619
Carvedilol92$563
Nitroglycerin41$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40$58,85645 claims
Johnson & JohnsonXarelto$87$43,11032 claims
Boehringer IngelheimJardiance$107$35,88431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 142 primary care providers in Virginia.

Other primary care in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →